Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
ABEONA THERAPEUTICS INC. | Chief Financial Officer | Common stock | 400K | $2.04M | $5.11 | Oct 8, 2021 | Direct |
Dianthus Therapeutics, Inc. /DE/ | CHIEF ACCOUNTING OFFICER | Stock Option (Right to Buy) | 60K | May 23, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
DNTH | Dianthus Therapeutics, Inc. /DE/ | May 23, 2024 | 1 | $0 | 4 | May 28, 2024 | CHIEF ACCOUNTING OFFICER |
DNTH | Dianthus Therapeutics, Inc. /DE/ | Jan 24, 2024 | 1 | $0 | 4 | Jan 26, 2024 | CHIEF ACCOUNTING OFFICER |
MGTA | Dianthus Therapeutics, Inc. /DE/ | Sep 11, 2023 | 0 | $0 | 3 | Sep 13, 2023 | CHIEF ACCOUNTING OFFICER |
ABEO | ABEONA THERAPEUTICS INC. | Oct 8, 2021 | 1 | -$30.6K | 4 | Oct 8, 2021 | Chief Financial Officer |
ABEO | ABEONA THERAPEUTICS INC. | Aug 10, 2021 | 2 | $0 | 4 | Aug 12, 2021 | Chief Financial Officer |